Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Double-blind	STARTED	Enalapril	444
Double-blind	STARTED	Sacubitril/Valsartan (LCZ696)	443
Double-blind	Treated Patients	Enalapril	436
Double-blind	Treated Patients	Sacubitril/Valsartan (LCZ696)	439
Double-blind	COMPLETED	Enalapril	348
Double-blind	COMPLETED	Sacubitril/Valsartan (LCZ696)	352
Double-blind	NOT COMPLETED	Enalapril	96
Double-blind	NOT COMPLETED	Sacubitril/Valsartan (LCZ696)	91
Open-label	STARTED	Enalapril	0
Open-label	STARTED	Sacubitril/Valsartan (LCZ696)	887
Open-label	COMPLETED	Enalapril	0
Open-label	COMPLETED	Sacubitril/Valsartan (LCZ696)	835
Open-label	NOT COMPLETED	Enalapril	0
Open-label	NOT COMPLETED	Sacubitril/Valsartan (LCZ696)	52

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02554890/flow